GLP-1 Receptor Agonists: How Early Is Appropriate?

Slides:



Advertisements
Similar presentations
Consider this Combo: GLP-1 Receptor Agonists and Basal Insulin Matt Heinsen, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health.
Advertisements

Diabetes Update Part 2 of 3 Division of Endocrinology
What's New in Basal Insulin for Diabetes
Copyright © 2015 by the American Osteopathic Association.
2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2
Copyright © 2015 by the American Osteopathic Association.
Short-, Intermediate-, Long-Acting Insulins
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Applying Data to Practice
CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?
Special Consideration in Insulin Therapy
Faster-Acting Insulins
Updates on Emerging GLP-1 Receptor Agonists
Modern Strategies for Basal Insulin Use in T2D
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Insulin Innovation.
Differentiating Among Incretin Agents for Type 2 Diabetes: Weighing the Evidence.
Updates on Outcomes for Novel T2D Therapies
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.
Agenda. Insulin Intensification Strategies: An Expert Perspective from Asia-Pacific.
How Early Should Basal Insulin Be Used in T2D Management?
Updates Abound.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Working as a Team for Improved Patient Outcomes in Type 2 Diabetes
Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Our Current Armamentarium for the Management of Type 2 Diabetes
Emerging Basal Insulins for Diabetes
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.
Early and Intensive T2D Management:
Antihyperglycemic therapy in type 2 diabetes: general recommendations
Insulin Use in Primary Care: Practice Challenges
Insulin Innovation.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Novel Approaches to T1D Management
Antihyperglycemic Therapy
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
CV Outcomes and Adherence With GLP-1 RAs
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Program. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes.
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Patient Selection for Modern T2D Agents
Improving Effective Basal Insulin Use in Clinical Practice
Improving Overall Health
Deep Dive: Examining Emerging GLP-1 RAs From a Clinical Perspective
Emerging Combination Injectable Therapy A New Era in Diabetes Care
ADA/EASD general recommendations for type 2 diabetes management (1).
Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists.
Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).
Fixed-Ratio Combination Therapy in T2DM
Antihyperglycemic therapy in adults with type 2 diabetes
Emerging Basal Insulins for Diabetes
Fresh perspectives ON BASAL Insulins in diabetes care
Presentation transcript:

GLP-1 Receptor Agonists: How Early Is Appropriate?

Goals

Differentiation of GLP-1-RAs

Antihyperglycemic Therapy in Type 2 Diabetes: General Recommendations

Potential Clinical Advantages of GLP-1 Receptor Agonists

Physiologic Effects of GLP-1 Receptor Agonists

Potential for GLP-1 RAs as First-Line Therapy

Choosing Between Agents With Low Rates of Hypoglycemia

Potential Clinical Disadvantages of GLP-1 Receptor Agonists

Potential of Once-Weekly GLP-1 Receptor Agonists: Exenatide QW

Combining Basal Insulin With a GLP-1 Receptor Agonist

Fixed Formulation

Once-Weekly GLP-1 RA in Combination With Basal Insulin*

Novel Emerging Strategies

Safety – Patient Education

Closing Comments

Abbreviations

References

References (cont)

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.